{"Clinical Trial ID": "NCT02165605", "Intervention": ["INTERVENTION 1:", "- HylaCare", "Each patient will be randomized blindly to determine whether the serum in the study will be applied to the mid- or lateral portion of the treated breast, using nipple as a dividing line. The product and placebo will also be applied to the contralateral breast in the same manner as an additional control. The study drug and placebo will be applied three times a day, but not within four hours before radiation therapy.", "INTERVENTION 2:", "- Placebo", "Each patient will be randomized blindly to determine whether the serum in the study will be applied to the mid- or lateral portion of the treated breast, using nipple as a dividing line. The product and placebo will also be applied to the contralateral breast in the same manner as an additional control. The study drug and placebo will be applied three times a day, but not within four hours before radiation therapy."], "Eligibility": ["Incorporation criteria:", "Women 18 years of age or older", "Diagnosis of breast cancer", "Intact breasts (not surgically absent)", "(for a total of 33 fractions) fractionated external radiation therapy planned to deliver by tangential beams opposed to 50.4 Gy in 28 fractions with a photon or an electron boost planned of 10Gy in 5 fractions", "\u2022 Ability to understand and meet the requirements of this study", "\u2022 Ability to give informed consent", "For sexually active women, the patient agrees to use an acceptable method of contraception", "- Exclusion criteria:", "Pregnant or lactating women", "The use of concomitant skin care preparations in any of the treated or control areas to be observed", "Any unhealed infection or injury in areas of the radiation therapy portal, or generalized dermatitis", "Creatinine in severe renal impairment > 3.0 within 6 months of registration of the study", "\u2022 Allergic history, including severe anaphylaxis or allergies to serum or placebo products under study", "\u2022 Planned relocation that would make follow-up visits impossible during the study", "A vascular collagen disease such as Lupus or scleroderma"], "Results": ["Performance measures:", "- Acute skin toxicity by NCI-CTC v4.0", "Version 4.0 of the NCI-CTC (National Cancer Institute-Common Terminology Criteria) was used to assess acute skin toxicity by the physician.", "Period: Week 5 during radiation therapy", "Results 1:", "Title of the arm/group: HylaCare", "Each patient will be randomized blindly to determine if the serum in the study will be applied to the mid- or lateral portion of the treated breast, using the nipple as a dividing line. The product and placebo will also be applied to the contralateral breast in the same manner as an additional control. The study drug and placebo will be applied three times a day, but not within four hours prior to radiation therapy.", "Total number of participants analysed: 28", "Type of measure: Number of participants", "Unit of measure: Participants Level 0: 3 10.7%", "Year 1 : 19 67.9%", "Grade 2: 6 21.4%", "Level 3: 0 0.0%", "Results 2:", "Title of the arm/group: Placebo", "Each patient will be randomized blindly to determine if the serum in the study will be applied to the mid- or lateral portion of the treated breast, using the nipple as a dividing line. The product and placebo will also be applied to the contralateral breast in the same manner as an additional control. The study drug and placebo will be applied three times a day, but not within four hours prior to radiation therapy.", "Total number of participants analysed: 28", "Type of measure: Number of participants", "Unit of measure: Participants Level 0: 3 10.7%", "Year 1: 18 64.3%", "Grade 2: 7,25.0%", "Level 3: 0 0.0%"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/28 (0.00 per cent)", "Adverse Events 2:", "- Yeah, that's right."]}